PM Tracker

Walmart’s expansion of coverage for abortions made headlines. Health insurance companies have coverage questions, however.

A spinal cord stimulation device newly approved in the U.S. one-ups other pain relief devices—or, perhaps, six-ups them—by treating multiple areas of the body at once.

A former Kadmon consultant pled guilty to insider trading ahead of Sanofi's September 2021 buyout of the small drugmaker. Frank Glassner made $368,000 trading off of nonpublic information, the feds say.

Windtree Therapeutics is taking weight off its branches, entering a global licensing deal with Lee’s Pharmaceutical and Zhaoke Pharmaceutical that offers more than $78.9 million in potential biobucks for several acute pulmonary pipeline treatments.

Despite the waning effects of the pandemic and an intact device portfolio, Medtronic started a new fiscal year on a slightly sour note.

Of the 1,400 jobs Novartis plans to cut in its home country of Switzerland, up to half will be leadership positions, the company said during a media event Tuesday in Zurich. The news comes after the company revealed in June that it would slash 8,000 jobs in order to save $1 billion.

Sen. Ron Wyden, D-Oregon, is probing marketing practices for Medicare Advantage and Part D plans, asking state regulators for the most common sources of consumer complaints.

Three months after the FDA sent a warning to Foghorn via a partial clinical hold on its phase 1 trial, regulators have become even more dismayed, downgrading the company's study to a full hold in light of additional patient deaths. 

Gilead is no stranger to antitrust lawsuits for its antiviral medicines, and now it's facing yet another in California. The Jacksonville Police Officers and Fire Fighters Health Insurance Trust is questioning the specifics of the company's 2014 patent settlement with Cipla.

The measure set was proposed by the Physicians Foundation and will be effective 2023. Hospitals will be required to report what portion of their population is screened for social drivers and how many screen positive in each category.

Not long after forging a partnership with Baxter earlier this year, Digital Diagnostics has roped in $75 million in series B funding to build out the reach of IDx-DR and its other AI-powered diagnostic tools, the company announced Tuesday.

Learn more about how the transition from early to late phase of a small molecule program plays a pivotal role in a program’s ultimate success.

Advanced research requires advanced tools. Our next-generation ELISA takes a fraction of the time to run eight analytes simultaneously while saving your sample volume. Simply load, scan, and insert your cartridge and come back to fully analyzed results in 75 minutes. Rethink your ELISA, with Ella.

Set a solid foundation for successful scale-up of buffer preparation.

The TrialCard/Triangle Insights Group platform is uniquely positioned to support you as your asset progresses through the value chain, by integrating strategic commercialization and market access insights with comprehensive patient and provider support services.

See how integration of innovative genetic analysis techniques into drug development is driving biopharma & biotech companies ahead.

What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations?

Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care.

What are key considerations for intranasal delivery in the treatment of acute and chronic conditions?

Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound.

How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market?

Carla Vozone discusses the significant trends in the OINDP segment including large molecules and novel indications, changes within CDMOs and various challenges facing the industry.

Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays?

Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar.